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Abstract
Purpose Manifestations of COVID-19 are primarily respiratory based, however, gastrointestinal symptoms are now recognized as an important component of the disease. The purpose of this study is to evaluate differences in abdominal pelvic CT
findings in the emergency department by COVID-19 test result.
Methods This retrospective study identified patients tested by PCR for COVID-19 infection who underwent abdominal pelvic
CT scan in the ED across an academic health system from March 15 to April 15, 2020. Radiology reports were reviewed for
the presence of ground glass opacity in the lungs and acute abdominal pathology. A subset of patients with acute abdominal
pathology were identified with inflammatory pathology in organs with high ACE2 receptor expression including bowel,
pancreas, urinary bladder, and kidney. CT findings for COVID positive versus negative patients were compared with Chisquare test.
Results 597 patients tested by PCR for COVID-19 infection underwent abdominal pelvic CT scan, 44% were COVID-19 positive. COVID-19 positive patients demonstrated significantly more ground glass opacity at the lung bases, 65.1%, (222/341)
versus 12.4% (33/266), p < 0.001), and significantly less acute abdominal findings, 23.8% (81/341) versus 45.5% (121/266),
p ≤ 0.001). When abdominal pathology was present, COVID-19 positive patients had higher rate of inflammatory pathology
58% (47/81) versus 29.8% (36/121).
Conclusions In patients undergoing abdominopelvic CT from the ED, COVID-19 positive patients are more likely to have
ground glass opacities at the lung bases and less likely to have acute abdominal pathology compared with COVID-19 negative patients. Further, COVID-19 positive patients are more likely to have inflammation of organs with high expression of
ACE2 receptors than other types of acute abdominal pathology.
Keywords COVID-19 · Abdominal pelvic CT · ACE2 receptor · Emergency radiology · Computed tomography ·
Gastrointestinal symptoms
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COVID-19 pandemic has infected over 23.9 million people
with over 821,000 deaths worldwide as of August 26, 2020
[1]. Many articles document COVID-19 imaging findings,
yet most focus on thoracic abnormalities [2, 3]. However,
COVID-19 has been shown to demonstrate multisystem and
not just thoracic involvement [4].
Gastrointestinal symptoms including diarrhea, vomiting,
and abdominal pain were initially reported at low rates, yet
are now seen in 12–50% of patients and are considered an
important aspect of the disease [5–9]. Lin et al. found 11.6%
of patients with COVID-19 and respiratory symptoms also
had GI symptoms on admission, which increased to 49.5%
during hospitalization. In one study, 6% of patients with
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COVID-19 presented with abdominal symptoms without
any respiratory abnormalities [10]. Virus shedding has been
detected in feces in over 40% of infected patients [11].
Imaging studies for acute non-respiratory symptoms
in COVID-19 patients are often negative. Hossain et al.
reported no acute abdominal findings in (68%) 69/101
patients of COVID-19 patients on abdominal pelvic CT
scan. When abdominal pathology is present, the bowel is
often affected. Goldberg-Stein et al. reported abdominal pelvic pathology in 57% of COVID-19 positive patients with
31% showing GI tract abnormalities [12]. Bhayana et al.
found 31% of CT scans had bowel pathology in patients with
COVID-19. The authors note a high level of Angiotensinconverting enzyme 2 (ACE2) receptors in the bowel, and
offer this as a possible explanation of these findings [13].
SARS-CoV-2 is known to enter the host cell via these receptors. While these were initially described in the lung, organs
elsewhere in the body are now known to have high expression. In addition to bowel, organs in the abdomen described
to have high expression of ACE2 receptors include the pancreas, kidneys, and bladder [14–20].
In the emergency department, clinical decisions regarding
the imaging of patients must be made prior to the availability of COVID-19 PCR test results. In some cases, patients
presenting with abdominal symptoms may not undergo PCR
testing prior to imaging. Radiologists have been the first
to suggest the diagnoses of COVID-19 infection based on
the presence of ground glass opacities at the lung bases in
patients presenting with abdominal symptoms [21]. In addition, we postulated that COVID-19 positive patients might
demonstrate acute pathology in the abdomen that differs
from COVID-19 negative patients, possibly due to the presence of high ACE2 receptor expression in certain organs.
Therefore, patients presenting with significant abdominal
symptoms warranting abdominal pelvic CT scan during the
COVID-19 pandemic are an important cohort to evaluate. To
our knowledge, no study has directly compared abdominal
pelvic CT scan findings for COVID-19 positive and negative
patients. Our goal was to determine if patients who ultimately tested positive for COVID-19 infection had different
rates and types of abdominal pathology reported on abdominal pelvic CT scans.

Materials and methods
Study design, setting, and population
This retrospective study evaluated consecutive adult patients
tested for COVID-19 infection who underwent abdominal
pelvic CT scan in the emergency department across an
academic health system from March 15 to April 15, 2020.

13

Patients were excluded if they were not tested for COVID-19
within 24 h of the CT or the study was performed for evaluation of trauma. If a patient underwent multiple CT studies,
only the initial study was evaluated. The hospital system
includes 12 hospital, 5 which are tertiary and 7 of which are
community based. Dates were chosen to correspond to early
onset to the peak of the COVID pandemic in our region.
The study was performed with approval of the institutional
review board and waiver of consent.

Data variables and collection
All CT studies of the abdomen and pelvis (with contrast,
without contrast, and without/with contrast) performed
within the study timeframe were identified by searching
the radiology information system (RIS). Demographic
information (age, gender, race) and COVID-19 PCR
testing status were extracted from the system electronic
health record system for all patients included in the study.
COVID-19 status was determined by nasal swab PCR
result in the ED or during the hospital admission. All
facilities used the same PCR test. The COVID-19 tests
could have been acquired 24 h before or after the CT.

Radiology report analysis
Radiology reports from the abdominal pelvic CT scans
were evaluated for the presence of ground glass opacities (GGO) at the lung bases, acute abdominal pathology,
including a subset of inflammatory pathology. The impression of the radiology report was reviewed to characterize CT findings and when unclear, the entire report and/
or images were evaluated. Evaluation of all reports and
studies were performed by a single board-certified radiologist fellowship trained in body imaging with 24 years
of experience (SF) blinded to clinical data outside of the
radiology report.
The presence of GGO at the lung bases was considered
based on report impression, and if unclear, full radiology report and/or image evaluation. If a concomitant chest
CT scan was reported, only the results of the lung bases
were considered. Focal consolidation reported as bacterial
pneumonia or atelectasis were not considered GGO.
Intraabdominal pathology was classified as acute
abdominal pathology (“abdominal pathology”) or as the
absence of acute abdominal pathology (“no abdominal
pathology”). A subset of patients with acute abdominal
pathology were identified with inflammatory pathology
in organs with previously reported high ACE2 receptor
expression including bowel, pancreas, urinary bladder,
and kidney. The presence or absence and type of acute
abdominal pathology was considered based on report
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impression. Acute abdominal pathology was defined by
any inflammatory, infectious or obstructing etiologies,
thromboses, hemorrhage, and neoplasm that could cause
acute symptoms. Chronic or asymptomatic conditions such
as hepatic steatosis, post-surgical biliary dilation, cirrhosis, diverticulosis, non-obstructing stones, neoplasm, and
degenerative changes in bone were not considered to be
acute pathology. In cases where the impression was vague,
the report was used to help clarify the impression. For the
few cases where the report was non-specific or vague, the
images were viewed directly by one of the radiologists
(SF) to determine the presence/absence of acute abdominal
pathology.

Statistical analysis
GGO, acute abdominal pathology, and inflammatory pathology in organs with high ACE2 receptor expression were
compared by COVID-19 result status for all patients. Further, the presence of abdominal pathology and inflammatory
pathology in organs with high ACE2 receptor expression
was compared by COVID-19 and GGO for all patients and
stratified by COVID and GGO findings. Statistical analyses
were performed using Chi square. Statistical significance
was considered for p value < 0.05. All statistical analyses
were done in SAS v9.4 (SAS Institute).

Results
Our initial search revealed 2375 ED patients who underwent
CT of the abdomen and pelvis within the study timeframe.
Patient cohort consisted of 597 patients (Fig. 1): 292 (48.9%)
men and 305 (51.1%) women in age groups 19–39 (17.6%),
40–59 (33.5%), 60–79 (34.3%), and 80+ (14.6%) (Table 1).
A total of 23/597 (3.9%) of cases had the images directly
reviewed. Results of COVID-19 PCR testing were negative
in 259 patients (43.4%) and positive in 338 patients (56.6%).
There were no significant differences in gender, age, race,
study location, or use of IV contrast by COVID result.
Findings on abdominal pelvis CT scan are summarized
in Tables 2, 3 and Figs. 2, 3, 4, 5, and 6. The absence of
abdominal pathology was more common in COVID-19 positive patients (258/338, 76.3%) compared with COVID-19
negative patients (140/259, 54.1%) (p < 0.001). Additionally, the absence of abdominal pathology was more common in patients with chest CT (109/144, 75.7%) compared
with patients without chest CT (289/453, 63.8%) (p = 0.027).
However, when acute intraabdominal pathology was
detected, COVID-19 positive patients were more likely to
have inflammation in an organ with high ACE2 expression
compared with COVID-19 negative patients (47/80, 58.8%

Fig. 1  Study design and patients
Table 1  Patient characteristics
Patient
characteristics
Sex
Male
Female
Age
19–39
40–59
60–79
80+
Race
Asian
African American
Other/unknown
White
Study location
Tertiary
Community
IV contrast
Yes
No
COVID status
Positive
Negative
Chest CT
No
Yes

Overall
N = 597

COVID−
N = 259

COVID+
N = 338

p value

292 (48.9%) 126 (48.6%) 166 (49.1%) 0.911
305 (51.1%) 133 (51.4%) 172 (50.9%)
105 (17.6%)
200 (33.5%)
205 (34.3%)
87 (14.6%)

53 (20.5%)
88 (34.0%)
87 (33.6%)
31 (11.2%)

37 (6.2%) 17 (6.6%)
82 (13.7%) 30 (11.6%)

52 (15.4%) 0.223
112 (33.1%)
118 (34.9%)
56 (16.6%)
20 (5.9%)
52 (15.4%)

0.091

195 (32.6%) 75 (29%)
120 (35.5%)
288 (47.4%) 137 (52.9%) 146 (43.2%)
402 (67.3%) 173 (66.8%) 229 (69%)
195 (32.7%) 86 (33.2%) 103 (31%)
457 (76.6%) 206 (79.5%) 251 (74.3%) 0.132
140 (23.5%) 53 (20.5%) 87 (25.7%)
338 (56.6%) NA
259 (43.4%) NA

NA
NA

NA

453 (75.6%) 196 (75.1%) 257 (75.6%) 0.919
144 (24%) 63 (24.1%) 81 (23.8%)
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and 35/119, 29.4%, respectively, p < 0.001). However, when
acute intraabdominal pathology was detected, there was no
difference between patients with versus without chest CT in
the presence of inflammation in an organ with high ACE2,
(16/35) 45.7% versus (66/164) 40.2%, respectively. Among
patients with inflammation in organs with high ACE2 receptors, the distribution of what organs were involved was the
same between those patients with and without COVID,
and with and without chest CT (p = 0.904 and p = 0.144,
respectively).
There was also no significant difference in the rate of
acute abdominal pathology by COVID-19 status in patients
with ground glass opacities (p = 0.094), yet in the subset
of patients without ground glass opacity at the lung bases,
the absence of abdominal pathology in COVID-19 positive
patients was seen more frequently (82/117, 70.1%) compared with COVID-19 negative patients (118/226, 52.2%)
(p = 0.002).

As expected, ground glass opacities were more commonly seen at the lung bases in COVID-19 positive patients
(221/338, 65.4%) than in COVID-19 negative patients
(33/259, 12.7%) (p < 0.001).

Discussion
Ground glass opacities are the most common lung finding
in COVID-19 seen in 56.4% of chest CT scans [6]. In our
study, we found 65.4% of COVID-19 positive patients had
ground glass opacities at the lung bases on abdominal pelvic
CT scan which was a significant difference from COVID19 negative patients (12.7%). This prevalence of ground
glass opacity in COVID-19 positive patients has been corroborated elsewhere. In a recent paper by Hossain et al., the
authors found that 63.9% of patents presenting to the ED
with neurologic or abdominal symptoms had GG opacities
in the lungs [4]. In our experience, especially at the onset

Table 2  Abdominal CT scan findings
Findings

All patients

COVID−

Ground glass opacity
GGO−
343 (57.5%) 226 (87.3%)
GGO+
254 (42.5%) 33 (12.7%)
Total
597
259
Abdominal pelvic CT findings in all patients
Inflammation in organs with high ACE2
82 (13.7%) 35 (13.5%)
receptors
Other acute abdominal pathology
117 (19.6%) 84 (32.4%)
No abnormal findings
398 (66.7%) 140 (54.1%)
Total
597
259
Type of abdominal pathology in those patients with acute findings
Inflammation in organs with high ACE2
82 (41.2%) 35 (29.4%)
receptors
Other acute abdominal pathology
117 (58.8%) 84 (70.6%)
Total
199
119
Inflammation in organs with high ACE2 expression
Bowel Inflammation
38 (46.3%) 15 (42.9%)
Pancreatitis
9 (11%)
4 (11.4%)
Pyelonephritis
8 (9.8%)
3 (8.6%)
Cystitis
27 (32.9%) 13 (37.1%)
Total
82
35
Other abdominal pathology details
Bowel obstruction
17 (14.5%) 15 (17.9%)
Acute cholecystitis
9 (7.7%)
7 (8.3%)
Hydronephrosis
20 (17.1%) 14 (16.7%)
Acute appendicitis
5 (4.3%)
4 (4.8%)
Diverticulitis
7 (6%)
4 (4.8%)
Other
59 (50.4%) 40 (47.6%)
Total
117
84
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p value

Without chest CT With chest CT p value

117 (34.6%) < 0.001 271 (59.8%)
221 (65.4%)
182 (40.2%)
338
453

72 (50%)
72 (50%)
144

0.038

47 (13.9%)

16 (11.1%)

0.027

< 0.001 66 (14.6%)

33 (9.8%)
258 (76.3%)
338

98 (21.6%)
289 (63.8%)
453

19 (13.2%)
109 (75.7%)
144

47 (58.8%)

< 0.001 66 (40.2%)

16 (45.7%)

33 (41.3%)
80

98 (59.8%)
164

19 (54.3%)
35

0.551

23 (48.9%)
5 (10.6%)
5 (10.6%)
14 (29.8%)
47

0.904

28 (42.4%)
6 (9.1%)
8 (12.1%)
24 (36.4%)
66

10 (62.5%)
3 (18.8%)
0 (0%)
3 (18.8%)
16

0.144

2 (6.1%)
2 (6.1%)
6 (18.2%)
1 (3%)
3 (9.1%)
19 (57.6%)
33

0.439

16 (16.3%)
7 (7.1%)
19 (19.4%)
5 (5.1%)
7 (7.1%)
44 (44.9%)
98

1 (5.3%)
2 (10.5%)
1 (5.3%)
0 (0%)
0 (0%)
15 (78.9%)
19

0.128

0.918

31 (14%)
5 (15.2%)

0.863

Fig. 2  A 50-year-old male, COVID-19 PCR positive, presented with
bilateral lower lobe ground glass opacities (arrows) with no intraabdominal pathology reported (not shown)

0.768
0.929
0.789
0.890

16 (13.7%)
36 (14.2%)
46 (13.4%)
47 (13.9%)
35 (13.5%)
82 (13.7%)
Inflammation
in organ with
high ACE2

p value

101 (86.3%)
297 (86.6%)

31 (14%)

30 (13.3%)

5 (15.2%)

30 (13.3%)

196 (86.7%)

16 (13.7%)

101 (86.3%)
0.002

190 (86%)
28 (84.8%)

0.120
0.049

218 (85.8%
< 0.001

291 (86.1%)
p value

< 0.001

224 (86.5%)
515 (86.3%)
No inflammation in organ
with high
ACE2

119 (45.9%)
199 (33.3%)
Abdominal
pathology

35 (29.9%)
56 (22%)
143 (41.7%)
80 (23.7%)

190 (86%)

196 (86.7%)

28 (84.8%)

0.094

35 (29.9%)
45 (20.4%)

108 (47.8%)

11 (33.3%)

108 (47.8%)
45 (20.4%)
11 (33.3%)

82 (70.1%)
140 (54.1%)
398 (66.7%)
No abdominal
pathology

82 (70.1%)
198 (78%)
200 (58.3%)
258 (76.3%)

176 (79.6%)

118 (52.2%)

22 (66.7%)

118 (52.2%)
176 (79.6%)
22 (66.7%)

COVID+
COVID−
COVID+
COVID−
COVID−

GGO−
GGO+
GGO−
COVID+

GGO+

GGO−

GGO+

Patients without GGO
Patients with GGO
Patients without COVID
Patients with COVID
All patients
Overall

Table 3  Bivariate analysis of abdominal pathology by COVID status accounting for ground glass opacities N (%)
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Fig. 3  A 49-year-old male, COVID-19 PCR positive, presented with
left-sided abdominal pain, with thick-walled loop of small bowel
(arrow) with mild peri-enteric fat stranding, suggesting enteritis

of the pandemic before gastrointestinal manifestations were
widely recognized as a presenting symptom, the radiologist
was often first to suggest the diagnosis of COVID-19 when
ground glass opacities were visualized on abdominal pelvic
CT.
Another significant finding in this study is that COVID19 negative patients had more acute pathologic findings on
abdominopelvic CT scan than COVID-19 positive patients.
We theorize that patients who were COVID positive who
underwent CT were more likely to have milder disease due
to generalized COVID infection. However, patients without COVID infection with milder symptoms did not seek
medical care and were not included in this study. Thus, the
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Fig. 4  A 53-year-old female, COVID-19 PCR positive, presented with pelvic pain, with thick-walled loop of descending colon (arrow) with mild
peri-enteric fat stranding (short arrows), representing colitis

Fig. 5  A 23-year-old male, COVID-19 PCR positive, presented with
abdominal pain, with pancreatic enlargement, peri-pancreatic edema
(arrows), and fluid in left pararenal space (short arrows) consistent
with acute pancreatitis

positive rate in COVID-19 negative patients who did seek
medical care increased.
Another possible explanation for this finding is the welldocumented communication between the lung and the gut
called the “gut–lung” axis [10, 22, 23]. In this bidirectional
system, microbial metabolites and endotoxins released into
the blood from lung inflammation can alter the microbiome
of the gut leading to abdominal symptoms in the absence of
intraabdominal pathology. In our study, we also found that
patients without ground glass opacities at the lung bases had
less acute intraabdominal pathology, if they were COVID-19
positive. This may be due to non-visualized infection in the
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Fig. 6  A 75-year-old female, COVID-19 PCR negative, presented
with abdominal pain, with mesenteric edema (short arrows), dilated
ileum (arrows), and decompressed terminal ileum (arrow heads) consistent with small bowel obstruction

mid and upper lungs also affecting the gut via the gut–lung
axis producing secondary abdominal symptoms. Alternatively, this may be due to the limited ability of abdominal
pelvic CT scan to detect mild inflammation or be compounded by the lack of IV contrast in 23.5% of studies. We
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did not find a statistical difference between COVID-19 negative and positive patients’ rate of abdominal pathology when
ground glass opacities were present. This might be explained
by possible lung inflammation in the COVID-19 negative
group from causes other than COVID-19 also affecting the
gut via the same axis.
In our study, we tracked the most common acute diagnoses mentioned in the impression of the radiology report that
could account for abdominal pain and compared COVID19 positive and negative patients. In the subset of patients
that had acute pathology, COVID-19 positive patients had
bowel inflammation, pancreatitis, pyelonephritis, or cystitis
more often than COVID-19 negative patients. Of those with
acute abdominal pathology, our most common diagnosis
was bowel inflammation seen in (23/80) 28.8% of COVID19 positive cases. This is similar to the 31% reported by
Bhayana et al. This trend was not seen when we looked at
COVID-19 negative patients. One possible explanation is
that organs with high ACE 2 receptor expression may be at
increased risk for tissue injury and inflammation by SARSCoV-2. This virus is also known to cause liver injury [24],
although periportal edema or heterogeneously enhancing
parenchyma was not documented in any report impressions
in our study. There is also increased ACE 2 receptor expression in the biliary tree [25], although we did not have any
cases of cholangitis. This may be due to the poor sensitivity
of CT for this diagnosis.
A limitation of our study is that we relied primarily on
the original radiology report impressions to compile our
data without reinterpretation of the images. This may be
an opportunity for future research. There can be variability
between radiologist’s interpretations and whether a diagnosis is reported as definitive or qualified in some manner.
Additionally, the radiology reports were analyzed by a single reader. In addition, we did not analyze our results with
respect to IV or oral contrast. Nonetheless, we had the same
limitations in both of our groups. Another limitation is the
variability of the RT-PCR test results which includes the
possibility of false-positive and false-negative results. An
additional limitation was the inability to account for hepatic
steatosis. This was because of the variability in reporting
and variability in use of IV contrast. This is an important
area for future research. Inclusion of only ED patients who
underwent abdominal imaging excluded patients who underwent imaging in the outpatient setting. Further, the etiology
of the underlying process of the inflammatory process was
not determined in this study. As such, we did not attempt to
differentiate between inflammation secondary to bacterial
infection, viral infection, or other non-infectious etiology.
Finally, this study determines correlation and not causality
between COVID-19 and organ involvement of disease.

Conclusion
In patients undergoing abdominopelvic CT from the ED,
COVID-19 positive patients are more likely to have ground
glass opacities at the lung bases and less likely to have acute
abdominal pathology compared with COVID-19 negative
patients. Further, COVID-19 positive patients are more
likely to have inflammation of organs with high expression
of ACE2 receptors than other types of acute abdominal
pathology.
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